학술논문
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study
Document Type
Article
Author
Source
Subject
*HIV
*LAMIVUDINE
*TENOFOVIR
*DOLUTEGRAVIR
*CLINICAL trial registries
*
*
*
*
Language
ISSN
2328-8957
Abstract
TANGO results have established the durable efficacy of dolutegravir/lamivudine in virologically suppressed individuals who switched from 3- or 4-drug tenofovir alafenamide (TAF)–based regimens. In this post hoc subgroup analysis, 144-week efficacy and tolerability of dolutegravir/lamivudine in participants who switched from elvitegravir/cobicistat/emtricitabine/TAF were consistent with the overall switch population. Clinical Trials Registration NCT03446573. [ABSTRACT FROM AUTHOR]